Invivo Anti-Mouse TSLP Recombinant mAb

TSLP (Thymic Stromal Lymphopoietin) is a four-helix-bundle cytokine belonging to the IL-2 family, initially discovered in thymic stromal cells, and is primarily produced by epithelial cells (such as those in the skin, intestinal tract, and lung barriers), mast cells, and dendritic cells. Structurally, it contains a C-terminal region critical for receptor binding and exists in two isoforms—a major functional form known as the long isoform, which binds to a heterodimeric receptor complex composed of TSLPR (CRLF2) and IL-7Rα, subsequently driving downstream immune responses through activation of the STAT5 signaling pathway. As a "master switch" cytokine positioned at the most upstream level of the allergic inflammatory cascade, TSLP functions to activate dendritic cells and promote the polarization of naive T cells toward the Th2 phenotype, triggering the release of type 2 cytokines including IL-4, IL-5, and IL-13, thereby playing a critical role in the pathogenesis of allergic diseases such as atopic dermatitis, asthma, and allergic rhinitis. Given its apex position in the allergic cascade, TSLP has become an important drug target for treating severe asthma and other allergic conditions, with the anti-TSLP monoclonal antibody Tezepelumab having been approved for clinical use, demonstrating broad-spectrum anti-inflammatory activity without restriction to specific Th2-high patient phenotypes.